Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Katerina S. Grechukhina"'
Publikováno v:
Современная онкология, Vol 26, Iss 2, Pp 182-189 (2024)
The classification of breast cancer (BC) by immunohistochemical phenotypes is widely used in routine clinical practice. However, the genetic profile of the tumor does not always correspond to the pathomorphological one, which can significantly affect
Externí odkaz:
https://doaj.org/article/9bd059acb1804b48b14f790646bef706
Autor:
Liudmila G. Zhukova, Larisa V. Bolotina, Victoria V. Dvornichenko, Natalia V. Fadeeva, Inna P. Ganshina, Katerina S. Grechukhina, Alfiya I. Hasanova, Nikolay V. Kislov, Igor Yu. Kudryavtsev, Alexey G. Manikhas, Natalia E. Musaeva, Alexandra A. Nizhegorodtseva, Olga E. Sadikova, Dina D. Sakaeva, Anton V. Snegovoy, Daniil L. Stroyakovskiy, Sergei A. Tjulandin, Ekaterina A. Trishkina, Liubov Iu. Vladimirova, Nikita M. Volkov, Yulia V. Kostalanova
Publikováno v:
Современная онкология, Vol 26, Iss 1, Pp 56-64 (2024)
Background. The use of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy is a key initial treatment for advanced luminal HER2-negative (HR+/HER2-) breast cancer. The approval studies MONALEESA-2 and 7 demonstra
Externí odkaz:
https://doaj.org/article/38d513dc74f248e7bd74c0e83c57a19a
Autor:
Katerina S. Grechukhina, Maxim V. Kalugin, Andrey A. Prosvirnov, Margarita V. Sukhova, Liudmila G. Zhukova
Publikováno v:
Современная онкология, Vol 25, Iss 1, Pp 55-62 (2023)
An increase in the median progression-free survival when using cyclin-dependent kinase 4/6 inhibitors in combination with aromatase inhibitors led to high expectations from the analysis of the overall survival of patients with HR+/HER2- metastatic br
Externí odkaz:
https://doaj.org/article/c5a35aa69a34445b8837d2b8b2b42e5a
Autor:
Katerina S. Grechukhina, Karina A. Vorontsova, Daria A. Filonenko, Pavel S. Tyutyunnik, Victoria V. Shchadrova, Liudmila G. Zhukova
Publikováno v:
Современная онкология, Vol 24, Iss 3, Pp 373-379 (2022)
Metastatic luminal B HER2-negative breast cancer (HR+/HER2- mBC) occupies a leading place in the global structure of morbidity and mortality among women. The current gold standard of first-line treatment is the combination of CDK4/6 inhibitors with a
Externí odkaz:
https://doaj.org/article/e339e930f9864adeba2b3549e8696fc5
Autor:
Katerina S. Grechukhina, Natalia V. Chebotareva, Liudmila G. Zhukova, Tatiana V. Androsova, Vladimir V. Karpov, Tatiana N. Krasnova
Publikováno v:
Терапевтический архив, Vol 94, Iss 6, Pp 725-730 (2022)
Background. Antiangiogenic drugs are widely used in oncological practice and are aimed at inhibiting angiogenesis. Despite the high antitumor efficacy, their use may be limited by nephrotoxicity, and therefore the search for early biomarkers of kidne
Externí odkaz:
https://doaj.org/article/9762bac841cd4ef18e1882e292ab16b7
Autor:
Katerina S. Grechukhina, Natalia V. Chebotareva, Liudmila G. Zhukova, Alexey S. Dorofeev, Tatiana N. Krasnova
Publikováno v:
Современная онкология, Vol 24, Iss 1, Pp 119-124 (2022)
Background. Cisplatin is widely used in modern oncological practice. Despite high efficacy treatment with cisplatin is conjugated with high risk of nephrotoxicity. Approximately one third of patients develop renal disfunction after first injection of
Externí odkaz:
https://doaj.org/article/0a7d4a7ee7cc4d6cac22127683e2776e
Publikováno v:
Терапевтический архив, Vol 93, Iss 6, Pp 661-666 (2021)
Background. Anti-angiogenic anticancer drugs that block the vascular endothelial growth factor signaling pathway can cause renal damage. Assessment of the risk of nephrotoxicity allows developing optimal treatment approaches and ensuring the relative
Externí odkaz:
https://doaj.org/article/0edcacec007340eea597ef7b3d44e597
Publikováno v:
Терапевтический архив, Vol 92, Iss 6, Pp 93-98 (2020)
Neoangiogenesis is a basic factor for most physiological as well as pathological processes i.e. tumor metastases. The most important is vascular endothelium growth factor (VEGF) and its receptors (VEGFR1/2) in angiogenesis processes. Nowadays antiang
Externí odkaz:
https://doaj.org/article/1e83f6005a324ae48a663bd7c06c0352
Publikováno v:
Терапевтический архив, Vol 93, Iss 6, Pp 661-666 (2021)
Anti-angiogenic anticancer drugs that block the vascular endothelial growth factor signaling pathway can cause renal damage. Assessment of the risk of nephrotoxicity allows developing optimal treatment approaches and ensuring the relative safety of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1b7ffa0af2935d6527b63b3eaf9a88
https://pubmed.ncbi.nlm.nih.gov/36286831
https://pubmed.ncbi.nlm.nih.gov/36286831
Publikováno v:
Современная онкология, Vol 21, Iss 3, Pp 33-37 (2019)
The only option of systemic therapy for triple-negative breast cancer (TNBC) was cytotoxic chemotherapy until recently, moreover the unitary standard of care for metastatic forms was not strictly defined. That is why paradigm of the treatment remains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::423c7fdb6e2c125841e13a684d67a520
https://modernonco.orscience.ru/1815-1434/article/viewFile/33518/pdf
https://modernonco.orscience.ru/1815-1434/article/viewFile/33518/pdf